These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 10378864

  • 1. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH.
    J Neuroimmunol; 1999 Jan 01; 93(1-2):8-14. PubMed ID: 10378864
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A, Murray TJ, PROOF Study Investigators.
    Curr Med Res Opin; 2008 Apr 01; 24(4):1049-55. PubMed ID: 18315940
    [Abstract] [Full Text] [Related]

  • 3. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
    Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN, IMPACT Investigators.
    Neurology; 2002 Sep 10; 59(5):679-87. PubMed ID: 12221157
    [Abstract] [Full Text] [Related]

  • 4. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B, Jacobs LD.
    Drugs; 2000 Mar 10; 59(3):401-10. PubMed ID: 10776827
    [Abstract] [Full Text] [Related]

  • 5. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.
    Neurology; 2009 Jun 09; 72(23):1989-93. PubMed ID: 19506220
    [Abstract] [Full Text] [Related]

  • 6. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P, CHAMPS.
    Clin Ther; 2003 Nov 09; 25(11):2865-74. PubMed ID: 14693310
    [Abstract] [Full Text] [Related]

  • 7. [Magnetic resonance findings in the brain of patients with multiple sclerosis without oligoclonal bands in the cerebrospinal fluid].
    Mesaroc S, Drulović J, Lević Z, Perić V.
    Srp Arh Celok Lek; 2003 Nov 09; 131(1-2):31-5. PubMed ID: 14608859
    [Abstract] [Full Text] [Related]

  • 8. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
    Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy, University of British Columbia MS/MRI Research Group.
    Neurology; 2002 Nov 26; 59(10):1496-506. PubMed ID: 12451188
    [Abstract] [Full Text] [Related]

  • 9. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH.
    Ann Neurol; 1998 Jan 26; 43(1):79-87. PubMed ID: 9450771
    [Abstract] [Full Text] [Related]

  • 10. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
    Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S.
    Neurology; 2000 May 09; 54(9):1741-5. PubMed ID: 10802778
    [Abstract] [Full Text] [Related]

  • 11. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM, Rudick RA, Munschauer FE, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.
    Mult Scler; 2005 Aug 09; 11(4):409-19. PubMed ID: 16042223
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
    Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW, European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators.
    Neurology; 2002 Nov 26; 59(10):1507-17. PubMed ID: 12451189
    [Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis.
    Ferraro D, Trovati A, Bedin R, Natali P, Franciotta D, Santangelo M, Camera V, Vitetta F, Varani M, Trenti T, Gastaldi M, De Biasi S, Nasi M, Pinti M, Meletti S, Sola P.
    Eur J Neurol; 2020 Mar 26; 27(3):461-467. PubMed ID: 31710409
    [Abstract] [Full Text] [Related]

  • 14. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 15. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP.
    Eur J Neurol; 2001 Mar 10; 8(2):141-8. PubMed ID: 11284992
    [Abstract] [Full Text] [Related]

  • 16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 10; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 17. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 18. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
    Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE.
    Neurology; 2000 Jul 25; 55(2):185-92. PubMed ID: 10908888
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Voortman MM, Stojakovic T, Pirpamer L, Jehna M, Langkammer C, Scharnagl H, Reindl M, Ropele S, Seifert-Held T, Archelos JJ, Fuchs S, Enzinger C, Fazekas F, Khalil M.
    Mult Scler; 2017 Oct 25; 23(11):1496-1505. PubMed ID: 27899552
    [Abstract] [Full Text] [Related]

  • 20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 25; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.